Navigation Links
European Patent Office Upholds GlideScope® Video Laryngoscope Patent
Date:8/20/2010

BOTHELL, Wash., Aug. 20 /PRNewswire/ -- The European Patent Office ("EPO") Board of Appeals has issued a formal written decision to uphold European Patent No. EP 1307131 for Verathon Inc.'s GlideScope video laryngoscopes.

(Logo: http://photos.prnewswire.com/prnh/20061011/SFW044LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20061011/SFW044LOGO)

The ruling, issued on July 26th, keeps the GlideScope patent in force in several European countries, including the UK, Germany, France, Denmark, Ireland and Italy. The patent, which does not expire until 2021, also remains valid in several countries outside of Europe.

The GlideScope patent, originally granted in Europe in May 2005, was opposed by Aircraft Medical Limited at the European Patent Office in February 2006. Aircraft Medical, maker of the McGrath video laryngoscope, is based in Edinburgh, Scotland.

Verathon® prevailed at a hearing in October 2007, when the EPO's Opposition Division rejected Aircraft Medical's opposition and upheld the GlideScope patent with amended claims.

The EPO's formal written decision in July concludes the Appeal filed by Aircraft Medical against Verathon's patent and the previous decision by the Opposition Division upholding the GlideScope patent.

About GlideScope

GlideScope video laryngoscopes provide a consistently clear, real-time view of the airway and of endotracheal tube placement. Designed for "1st Pass Success," GlideScope instruments, which minimize the need for "blind" intubation procedures, come in both single use and reusable configurations, and in a variety of sizes for patients from preterm to morbidly obese.

About Verathon Inc.

Verathon designs and manufactures reliable, state-of-the-art medical devices and services that offer a meaningful improvement in patient care to the health care community. The company's noninvasive BladderScan® instrument is a standard of care for portable bladder volume measurement. The brand is found in over 60 countries in Urology and Primary Care practices, as well as Acute and Extended Care facilities. With the January 2006 acquisition of Saturn Biomedical Systems in Vancouver, Canada, Verathon entered Anesthesiology, Critical Care and Emergency markets with the GlideScope Video Laryngoscope (GVL®) brand. Verathon is headquartered in Bothell, Washington and operates as a subsidiary of Roper Industries. For more information, please visit www.verathon.com.

Media Contact:

Jane Mueller, VP of Marketing, 425.867.1348, Ext. 5600

Copyright 2010, Verathon Inc. GlideScope, GVL, BladderScan, their respective symbols, Verathon and the Verathon torch symbol are registered trademarks of Verathon Inc.


'/>"/>
SOURCE Verathon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
2. Cardiac Dimensions® Announces Presentation of 12-Month Follow-up Data of TITAN™ Trial at European Society of Cardiology Meeting
3. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
4. PDL BioPharma Receives Letter from Genentech Relating to European Patents
5. Western European Market for Image-guided and Robot-assisted Surgery
6. European Research Project Aims to Improve the Diagnosis and Therapy of Brain Diseases
7. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
8. Reportlinker Adds European Market for Ventilation and Airway Management Devices
9. Reportlinker Adds Western European Disinfectant Gels and Scrubs Market
10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
11. Reportlinker Adds European Markets for Gastrointestinal Endoscopic Devices 2010 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology:
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... Lake Park ... smiles by using Invisalign® in Lutz, FL. With the help of this ... and aesthetics with fewer potential complications, more discretion and less pain. , Drs. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
(Date:4/25/2017)... ... , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care ... on preventative care with all my patients to alleviate possible future issues. I am pleased ... contact my office and my trained staff will assist you in any way possible.” , ...
(Date:4/25/2017)... Hollywood, Fl (PRWEB) , ... April 25, 2017 , ... ... than Memorial Regional Hospital, according to a special report in the May issue of ... Hospital its highest quality ranking for results achieved during and after coronary bypass ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College ... nursing professionals advance their careers. Beginning in the fall of 2017, Emmanuel’s program will ... in as few as 16 months and for as little as $14,528. These changes ...
Breaking Medicine News(10 mins):